1
|
Weber CJ, Carrillo MC, Jagust W, Jack CR, Shaw LM, Trojanowski JQ, Saykin AJ, Beckett LA, Sur C, Rao NP, Mendez PC, Black SE, Li K, Iwatsubo T, Chang C, Sosa AL, Rowe CC, Perrin RJ, Morris JC, Healan AM, Hall SE, Weiner MW. The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives. ALZHEIMER'S & DEMENTIA (NEW YORK, N. Y.) 2021; 7:e12226. [PMID: 35005206 PMCID: PMC8719344 DOI: 10.1002/trc2.12226] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Accepted: 11/05/2021] [Indexed: 11/06/2022]
Abstract
The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.
Collapse
Affiliation(s)
| | | | - William Jagust
- School of Public Health and Helen Wills Neuroscience InstituteUniversity of California BerkeleyBerkeleyCaliforniaUSA
| | | | - Leslie M. Shaw
- Department of Pathology and Laboratory MedicinePerelman School of MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | - John Q. Trojanowski
- Department of Pathology and Laboratory MedicinePerelman School of MedicineInstitute on AgingPerelman School of MedicineAlzheimer's Disease Core Center, Perelman School of MedicineUdall Parkinson's Research CenterPerelman School of MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
| | - Andrew J. Saykin
- Department of Radiology and Imaging Sciences and the Indiana Alzheimer's Disease Research CenterDepartment of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisIndianaUSA
| | - Laurel A. Beckett
- Division of BiostatisticsDepartment of Public Health SciencesUniversity of CaliforniaDavisCaliforniaUSA
| | - Cyrille Sur
- Merck Research LaboratoriesMerckKenilworthNew JerseyUSA
| | - Naren P. Rao
- Department of PsychiatryNational Institute of Mental Health and NeurosciencesBengaluruKarnatakaIndia
| | | | - Sandra E. Black
- Department of Medicine (Neurology)Hurvitz Brain Sciences ProgramCanadian Partnership for Stroke Recovery, and LC Campbell Cognitive Neurology Research UnitHurvitz Brain Sciences Research ProgramSunnybrook Research InstituteSunnybrook Health Sciences CentreUniversity of TorontoTorontoCanada
| | - Kuncheng Li
- Department of RadiologyXuanwu Hospital of Capital Medical UniversityBeijingChina
| | - Takeshi Iwatsubo
- Department of NeuropathologyGraduate School of MedicineThe University of TokyoTokyoJapan
| | - Chiung‐Chih Chang
- Department of General Neurology and Institute for Translational Research in BiomedicineKaohsiung Chang Gung Memorial HospitalChang Gung University College of MedicineKaohsiungTaiwan
| | - Ana Luisa Sosa
- National Institute of Neurology and Neurosurgery of MexicoMexico CityMexico
| | - Christopher C. Rowe
- Department of Molecular Imaging and TherapyAustin Health and Florey Department of Neuroscience and Mental HealthUniversity of MelbourneMelbourneVictoriaAustralia
| | - Richard J. Perrin
- Charles F. and Joanne Knight Alzheimer Disease Research CenterDepartment of Pathology and ImmunologyDepartment of NeurologyWashington University School of MedicineSaint LouisMissouriUSA
| | - John C. Morris
- Charles F. and Joanne Knight Alzheimer Disease Research CenterDepartment of NeurologyWashington University School of MedicineSaint LouisMissouriUSA
| | | | | | - Michael W. Weiner
- Department of Veterans Affairs Medical CenterCenter for Imaging of Neurodegenerative DiseasesDepartment of RadiologyDepartment of MedicineDepartment of PsychiatryDepartment of NeurologyUniversity of CaliforniaSan FranciscoCaliforniaUSA
| |
Collapse
|
2
|
Damian A, Portugal F, Niell N, Quagliata A, Bayardo K, Alonso O, Ferrando R. Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country. Front Neurol 2021; 12:630958. [PMID: 34017300 PMCID: PMC8129494 DOI: 10.3389/fneur.2021.630958] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 04/06/2021] [Indexed: 12/03/2022] Open
Abstract
Introduction: The objective of this study was to evaluate the clinical impact PET with 18F-FDG and 11C-PIB in patients with dementia in a developing country. Methodology: Retrospective study of the patients referred for the evaluation of dementia to the only PET center in Uruguay. A total of 248 patients were identified, from which 70 patients were included based on the availability of medical history and clinical follow-up. Main outcomes included change in diagnosis, diagnostic dilemma and AD treatment. We evaluated the association of clinical outcomes with PET concordance with baseline diagnosis, diagnostic dilemma, level of education, AD pathology/Non-AD pathology (AD/Non-AD), baseline diagnosis and 11C-PIB PET result. Results: Baseline clinical diagnosis was concordant with 18F-FDG and 11C-PIB PET results in 64.7 and 77.1% of the patients, respectively. Change in diagnosis after PET was identified in 30.0% of the patients and was associated with discordant 18F-FDG (p = 0.002) and 11C-PIB (p < 0.001) PET results, previous diagnostic dilemma (p = 0.005), low education (p = 0.027), Non-AD baseline diagnosis (p = 0.027), and negative 11C-PIB PET result (p < 0.001). Only the last variable remained significant in the multivariate analysis (adjusted p = 0.038). Diagnostic dilemma decreased after PET from 15.7 to 7.1% (p = 0.11) and was associated with Non-AD diagnosis (p = 0.002) and negative 11C-PIB PET result (p = 0.003). Change in AD treatment after PET occurred in 45.7% of the patients. Conclusion:18F-FDG and 11C-PIB PET had a significant clinical impact in terms of change in diagnosis and treatment in patients with dementia in a developing country, similar to that reported in high-income countries.
Collapse
Affiliation(s)
- Andres Damian
- Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay.,Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, Uruguay
| | - Fabiola Portugal
- Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, Uruguay
| | - Nicolas Niell
- Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay.,Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, Uruguay
| | - Adriana Quagliata
- Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay
| | - Karina Bayardo
- Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, Uruguay
| | - Omar Alonso
- Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay.,Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, Uruguay
| | - Rodolfo Ferrando
- Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay.,Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, Uruguay
| |
Collapse
|
3
|
Biomarkers of Alzheimer disease in mild cognitive impairment: Experience in a memory clinic from Latin America. NEUROLOGÍA (ENGLISH EDITION) 2021. [DOI: 10.1016/j.nrleng.2017.12.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
4
|
Allegri RF. Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing "where" by "what"…. Dement Neuropsychol 2020; 14:237-242. [PMID: 32973977 PMCID: PMC7500817 DOI: 10.1590/1980-57642020dn14-030005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Neurodegenerative dementias have been described based on their phenotype, in relation to selective degeneration occurring in a particular neuroanatomical system. More recently however, the term proteinopathy has been introduced to describe diseases in which one or more altered proteins can be detected. Neurodegenerative diseases can be produced by more than one abnormal protein and each proteinopathy can determine different clinical phenotypes. Specific biomarkers have now been linked to certain molecular pathologies in live patients. In 2016, a new biomarker-based classification, currently only approved for research in Alzheimer's disease, was introduced. It is based on the evaluation three biomarkers: amyloid (A) detected on amyloid-PET or amyloid- beta 42 assay in CSF; tau (T) measured in CSF as phosphorylated tau or on tau PET imaging; and neuronal injury/neurodegeneration (N), detected by total T-tau in CSF, FDG PET hypometabolism and on MRI brain scan. Results of clinical research using the ATN biomarkers at FLENI, a Neurological Institute in Buenos Aires, Argentina have, since 2011, contributed to ongoing efforts to move away from the concept of neurodegenerative dementias and more towards one of cognitive proteinopathies. Today, clinical diagnosis in dementia can only tell us "where" abnormal tissue is found but not "what" molecular mechanisms are involved.
Collapse
Affiliation(s)
- Ricardo Francisco Allegri
- Departament of Cognitive Neurology, Neuropsychology, and Neuropsychiatry, Instituto de Investigaciones Neurologicas Fleni, Buenos Aires, Argentina.,Department of Neurosciences, Universidad de la Costa, Barranquilla, Colombia
| |
Collapse
|
5
|
Allegri RF, Chrem Méndez P, Calandri I, Cohen G, Martín ME, Russo MJ, Crivelli L, Pertierra L, Tapajóz F, Clarens MF, Campos J, Nahas FE, Vázquez S, Surace E, Sevlever G. Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2020; 12:e12026. [PMID: 32490138 PMCID: PMC7243942 DOI: 10.1002/dad2.12026] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 01/20/2020] [Accepted: 01/23/2020] [Indexed: 12/20/2022]
Abstract
PURPOSE To describe results of the Amyloid, Tau, Neurodegeneration (ATN) research framework classification in the Argentine-Alzheimer's Disease Neuroimaging Initiative (arg-ADNI) cohort. METHODS Twenty-three patients with mild cognitive impairment (MCI), 12 dementia of Alzheimer's type (DAT), and 14 normal controls were studied following the ADNI2 protocol. Patients were categorized according to presence or absence of the biomarkers for amyloid beta (Aβ; A: amyloid positron emission tomography [PET] scan or cerebrospinal fluid [CSF] Aβ42), tau (T: CSF phosphorylated-tau), and neurodegeneration (N: CSF total-tau, fluorodeoxyglucose [FDG]-PET scan, or structural magnetic resonance imaging [MRI] scan). RESULTS A+T+N+ biomarker profile was identified at baseline in 91% of mild dementia patients, 20% of early MCI patients, 46% of late MCI patients, and 14% of control subjects. Suspected non-AD pathophysiology (SNAP, A-T-N+) was found in 8% of mild dementia, 20% of early MCI, 15% of late MCI, and 7% of control subjects. Conversion rates to dementia after 5-year follow-up were 85% in A+T+N+ MCI patients and 50% in A-T-N+ patients. CONCLUSIONS We present initial 5-year follow-up results of a regional ADNI based on AD biomarkers and the ATN classification.
Collapse
Affiliation(s)
- Ricardo F. Allegri
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
- Department of NeurosciencesUniversidad de la Costa (CUC)BarranquillaColombia
| | - Patricio Chrem Méndez
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Ismael Calandri
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Gabriela Cohen
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Maria Eugenia Martín
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - María Julieta Russo
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Lucia Crivelli
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Lucia Pertierra
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Fernanda Tapajóz
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - María Florencia Clarens
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Jorge Campos
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Federico E. Nahas
- Department of Cognitive NeurologyNeuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Silvia Vázquez
- Center of Molecular NeuroimagingInstituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Ezequiel Surace
- Department of Molecular Biology and NeuropathologyInstituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| | - Gustavo Sevlever
- Department of Molecular Biology and NeuropathologyInstituto de Investigaciones Neurológicas FLENIBuenos AiresArgentina
| |
Collapse
|
6
|
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America. Neurologia 2018; 36:201-208. [PMID: 29636288 DOI: 10.1016/j.nrl.2017.12.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Accepted: 12/17/2017] [Indexed: 11/21/2022] Open
Abstract
OBJECTIVE This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. METHODS We studied 89 patients with MCI, 43 with Alzheimer-type dementia, and 18 healthy controls (matched for age, sex, and educational level) at our memory clinic (Instituto FLENI) in Buenos Aires, Argentina. Patients and controls underwent an extensive demographic, neurological, and neuropsychological assessment. All subjects underwent a brain MRI scan; FDG-PET scan; amyloid PET scan; apolipoprotein E genotyping; and cerebrospinal fluid concentrations of Aβ1-42, tau, and phosphorylated tau. Patients were categorised as positive or negative for the presence of amyloid pathology and neurodegeneration. RESULTS Amyloid pathology was observed in cerebrospinal fluid results in 18% of controls, 64% of patients with MCI, and 92% of patients with Alzheimer-type dementia. Suspected non-Alzheimer disease pathophysiology was found in 11% of controls, 6% of patients with MCI, and 8% of patients with Alzheimer-type dementia. At 30 months of follow-up, 45% of amyloid-positive patients with MCI and 20% of amyloid-negative patients with MCI showed progression to dementia. CONCLUSIONS This study demonstrates biomarker-based MCI prognosis and supports its role in clinical decision-making in daily practice.
Collapse
|